Jill Wechsler, Pharm Exec’s Washington Correspondent

Jill Wechsler is Pharm Exec's Washington Corespondent


FDA to Continue Inspection Efficiencies After Pandemic

Plan to keep new methods adopted during COVID in place.

Escalating Abortion Battle Threatens FDA Authority

Access to mifepristone, approved by the agency in 2000, also under microscope.

Congress Presses FDA on Key Policies and Operations

Medical device user-fees agreement, Aduhelm approval and access among issues in crosshairs.

Clinical Trial Diversity Advances in Regulatory Agenda

Dual efforts focused on more inclusive research and more diverse enrollment in pre- and post-approval studies.

FDA Revives Initiative to Identify and Reward Quality Drug Operations

Program looks to establish framework for agency and purchasers to “objectively rate” manufacturing sites.